The effect of C 2 -ceramide, a membrane-permeable ceramide analogue, on nitric oxide (NO) production in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells was studied. The non-toxic concentration of C 2 -ceramide inhibited LPS-induced NO production. It was due to the attenuated expression of the inducible type of NO synthase (iNOS). C 2 -ceramide did not influence the phosphorylation of a series of mitogen-activated protein (MAP) kinases in response to LPS. On the other hand, C 2 -ceramide down-regulated the phosphorylation of Akt in LPS-stimulated RAW 264.7 cells, followed by the impairment of nuclear factor (NF)-kB activation. Moreover, the Akt dominant-negative mutant inhibited LPS-induced NO production. C 2 -ceramide was suggested to inhibit LPS-induced NO production through down-regulating the activation of Akt.
INTRODUCTION
Bacterial lipopolysaccharide (LPS) shows strong structural and functional resemblance to ceramide. 1, 2 Ceramide is an intracellular second messenger that can be generated by sphingomyelin membrane cleavage using either acid or neutral sphingomyelinases. 3, 4 Intracellular ceramide has been reported to participate as a signal molecule in LPSinduced activation of macrophages. [5] [6] [7] [8] [9] Membrane-permeable ceramide analogs have often been used to investigate the function of cellular ceramide in LPS signaling.
In RAW 264.7 macrophage cell lines, ceramide analogs have been shown to modulate the production of nitric oxide (NO). 10, 11 NO production by macrophages is important for killing bacteria, but excessive NO production leads to inflammatory responses and tissue damage. 12 Since cellpermeable analogs of ceramide regulate NO production and an inducible NO synthase (iNOS), 10 it was of interest to determine how ceramide analogs modulate LPSinduced NO production. Recently, C 2 -ceramide has been reported to inhibit LPS-induced NO production through the inactivation of nuclear factor (NF)-kB, mitogen-activated protein (MAP) kinases and protein kinase C. 11 On the other hand, C 2 -ceramide is reported to mimic LPS in activating MAP kinases, but not in mediating NF-kB induction. 13 There is no report on the involvement of phosphatidylinositol 3 (PI3)-kinase/Akt in the inhibition of LPS-induced NO production by C 2 -ceramide, although C 2ceramide is known to inhibit Akt phosphorylation in response to a various of stimuli. [14] [15] [16] [17] [18] [19] In the present study, we investigated the detailed mechanism of how C 2ceramide inhibited NO production and iNOS expression in LPS-stimulated RAW 264.7 cells.
MATERIALS AND METHODS

Reagents
Escherichia coli O55 LPS, C 2 -ceramide (N-acetyl-Dsphingosine), dihydro-C 2 -ceramide and neomycin were purchased from Sigma Chemical (St Louis, MO, USA). A series of antibodies to Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), p38, stress-activated protein kinase/c-Jun NH 2 -terminal kinase (SAPK/JNK) and their phosphorylated forms were obtained from New England Biolabs (Beverly, MA, USA). The anti-mouse iNOS antibody was purchased from ABR (Golden, CO, USA). LY294002 as an inhibitor of PI3-kinase, SB202190 as an inhibitor of p38 MAP kinase, and PD98059 as an inhibitor of ERK1/2 MAP kinase were obtained from Calbiochem (Darmstadt, Germany). The Akt allelic pack containing the Akt dominant-negative mutant and its empty vector were purchased from Upstate (Lake Placid, NY, USA).
Cell culture
The RAW 264.7 macrophage cell line was obtained from Riken Cell Bank (Tsukuba, Japan). The cells were cultured in DMEM supplemented with antibiotic (Sigma) and 5% fetal bovine serum (HyClone, Logan, UT, USA) at 37°C under 5% CO 2 .
Determination of nitrite concentration
NO was measured as its end product, nitrite, using the Griess reagent as described elsewhere. 20 The culture supernatant (100 ml) was mixed with 100 ml of Griess reagent for 10 min, and the absorbance at 570 nm was measured in a microplate reader. The concentration of nitrite in the samples was determined with reference to a sodium nitrite standard curve. Data represent the mean of triplicate determinations with standard deviation (SD).
Immunoblotting
The immunoblotting procedure was conducted as described previously. 21 Briefly, RAW 264.7 cells were cultured with LPS (1 mg/ml) and/or C 2 -ceramide. The cells were lysed with a lysis buffer. The cell lysates were diluted with an equal volume of 2x sample buffer containing 0.5 M Tris-HCl, 4% SDS, 2 mM mercaptoethanol and boiled for 5 min. Samples were separated under reducing conditions by electrophoresis using 4-12% polyacrylamide gels. Proteins separated by gel electrophoresis were transferred to a membrane by electroblotting. The membranes were blocked with 5% skimmed milk in 0.01 M phosphate-buffered saline (PBS). After washing in PBS containing 0.05% Tween 20, they were treated with the appropriately diluted antibody to Akt, Erk1/2, p38, SAPK/JNK, phospho-Akt, phospho-Erk1/2, phospho-p38 or phospho-SAPK/JNK. Resulting immune complexes were reacted with a 1:1000 dilution of peroxidase-conjugated goat IgG to rabbit IgG F(ab¢)2 (Cappel, West Chester, PA, USA). Finally, labeled antigen bands were detected by a chemiluminescence reagent (NEN, Boston, MA, USA). Prestained protein marker from GibcoBRL (Rockville, MD, USA) was used as reference.
Luciferase reporter gene assay for NF-kB activation RAW 264.7 cells (3 x 10 5 /ml) were plated in 35-mm plastic dishes. On the following day, the cells were transfected with 0.5 mg of pNF-kB-Luc plasmid (a luciferase reporter gene driven by five tandem repeats of NF-kB; PathDetect System, Stratagene, La Jolla, CA, USA) and 0.5 mg of pCMV-b-gal plasmid (Gibco-BRL) by the lipofectin method (Gibco-BRL). 21 The transfected cells were treated with C 2 -ceramide and/or LPS for 8 h. The cells were lysed using the lysis reagent (Promega, Madison, WI, USA) and the luciferase activity was determined on cell lysates with a luminometer. The bgalactosidase activity was used to normalize transfection efficiencies. All bar diagrams are shown as the mean of duplicate determination with SD for two experiments in which each transfection was performed in duplicate.
Transfection of the Akt dominant-negative mutant
RAW 264.7 cells (2.5 x 10 5 /well) were cultured in a 24well plate. On the following day, the Akt dominant-negative mutant or empty vector (0.8 mg) was mixed with lipofectoamine 2000 (2 ml) and transfected to the cells according to manufacturer's protocol (Gibco-BRL). For drug selection, neomycin (0.8 mg/ml) was added 24 h after the transfection and the cells were further cultured for 48 h. The stable transfectants were used for experiments. The expression of Akt dominant-negative mutant was confirmed by immunoblotting using an anti-Myc tag antibody since the vectors carry Myc tag insert.
Statistical analysis
Experimental results are expressed as the mean ± SD. Statistical significance was determined by Student's t-test.
RESULTS
The inhibitory action of C 2 -ceramide on LPS-induced NO production
The effect of C 2 -ceramide on NO production was examined in LPS-stimulated RAW 264.7 cells (Fig. 1 ). The mixture of LPS (1 mg/ml) and C 2 -ceramide (7.5 or 15 mM) was added to the cultures and 24 h later the supernatants were collected for the measurement of NO. The addition of C 2 -ceramide at 7.5 and 15 mM inhibited LPS-induced NO production by approximately 70% and 50%, respectively (P < 0.01). C 2 -ceramide also reduced constitutive NO production in the cultures of RAW 264.7 cells in the absence of LPS. C 2 -ceramide at a concentration of 15 mM affected neither the cell viability nor growth. In addition, dihydro-C 2 -ceramide, an inactive analog of C2-ceramide, did not inhibit the NO production (data not shown). Subsequently, the effect of C 2 -ceramide on the expression of iNOS was studied by immunoblotting with an anti-iNOS antibody (Fig. 2) . C 2 -ceramide definitely prevented iNOS expression in LPS-stimulated RAW 264.7 cells, although LPS definitely induced iNOS proteins.
The inhibitory action of C 2 -ceramide on the activation of PI3-kinase/Akt signal pathway in LPS-stimulated RAW 264.7 cells
In preliminary experiments, LY294002, a PI3-kinase inhibitor, profoundly down-regulated LPS-induced NO production (data not shown), suggesting the involvement of PI3-kinase in LPS-induced NO production. The downstream molecule of the PI3-kinase pathway is the Akt molecule. C 2 -ceramide is reported to inhibit the Akt phosphorylation in response to various stimuli. [14] [15] [16] [17] [18] [19] Therefore, the effect of C 2 -ceramide on the constitutive phosphorylation of Akt was examined by immunoblotting with an anti-phosphorylated Akt antibody (Fig. 3) . RAW 264.7 cells were treated with C 2 -ceramide at 3, 7.5 or 15 mM for 60 min. The constitutive phosphorylation of Akt was inhibited by the addition of C 2 -ceramide in a concentration-dependent manner. Similarly, the effect C 2 -ceramide on the phosphorylation of Akt was studied in LPS-stimulated RAW 264.7 cells. Based on the finding that LPS-induced Akt phosphorylation continued from 15-90 min and reached a peak at 30-60 min in preliminary (Fig. 4 ). C 2 -ceramide alone induced the phosphorylation of p38 MAP kinase. However, there was no significant difference in the phosphorylation of p38 MAP kinase between C 2 -ceramide alone and the mixture of LPS and C 2ceramide, excluding the participation of p38 MAP kinase in the inhibition of LPS-induced NO production by C 2ceramide. Moreover, C 2 -ceramide did not affect LPSinduced phosphorylation of ERK1/2 and SAPK/JNK.
Effect of C 2 -ceramide on the activation of NF-kB activity in LPS-stimulated RAW 264.7 cells
The Akt signal molecule is known to play an important role in the activation of NF-kB. [22] [23] [24] [25] Further, NF-kB binds the iNOS promoter as a major transcription factor and is the most energetic regulator of LPS-induced NO production. [26] [27] [28] The effect of C 2 -ceramide on the activation of NF-kB was examined by the reporter gene assay with a luciferase activity (Fig. 5 ). C 2 -ceramide at 15 mM prevented the activation of NF-kB by about 50% in the presence of LPS (P < 0.01), although LPS alone markedly augmented it. The inhibition of NF-kB activation by C 2 -ceramide roughly paralleled that of NO production by C 2 -ceramide.
Effect of the Akt dominant-negative mutant on NO production in LPS-stimulated RAW 264.7 cells
The expression vector of the Akt dominant-negative mutant was introduced into RAW 264.7 cells and the stable transfectants were obtained by drug selection. The transfection of the Akt dominant-negative mutant, but not the empty vector, reduced the constitutive phosphorylation of Akt (data not shown). The effect of the Akt dominantnegative mutant on LPS-induced NO production was examined in stable transfectants (Fig. 6) . Transfection with the Akt dominant-negative mutant inhibited LPS-induced NO production by approximately 30% (P < 0.01), whereas the empty vector did not inhibit it. 
DISCUSSION
In the present study, we demonstrated that C 2 -ceramide might inhibit LPS-induced NO production by down-regulating the activation of Akt. Several lines of evidence suggest that C 2 -ceramide inhibits the activation of the PI3-kinase/Akt signal pathway in response to LPS: (i) C 2ceramide down-regulates the phosphorylation of Akt signal molecule in response to LPS; (ii) LY294002 inhibits NO production in LPS-stimulated RAW 264.7 cells; (iii) C 2 -ceramide inhibits the activation of NF-kB which is regulated by Akt; and (iv) the Akt dominant-negative mutant inhibits LPS-induced NO production. Therefore, C 2ceramide appeared to inhibit LPS-induced NO production through Akt-dependent NF-kB activation since NF-kB is known to be activated by Akt [14] [15] [16] [17] and a main regulator in the expression of iNOS proteins by LPS. [18] [19] [20] Previously, Hsu et al. 11 reported that C 2 -ceramide inhibition of LPSmediated induction of iNOS was due to the inactivation of NF-kB and AP-1. For the first time, we have demonstrated the role of Akt on the inhibition of LPS-induced NO production and NF-kB activation by C 2 -ceramide.
There are a number of reports on the inhibitory action of C 2 -ceramide on Akt activation in response to various stimuli. [14] [15] [16] [17] [18] [19] C 2 -ceramide appears to activate a phosphatase and to accelerate the dephosphorylation of Akt. [14] [15] [16] [17] [18] The phosphatase has been reported to be protein phosphatase-2A. 15, 18 On the other hand, C 6 -ceramide induces the inhibition of Akt through activation of protein kinase Czeta. 19 It is still unknown whether C 2ceramide inhibits LPS-induced Akt phosphorylation by dephosphorylation.
The present study demonstrated that C 2 -ceramide did not inhibit the activation of p38 MAP kinase in LPSstimulated RAW 264.7 cells. On the other hand, Hsu et al. 11 have reported that the activation of LPS-induced protein kinase C and p38 MAP kinase are overcome by ceramide. The discrepancy in its inhibitory action on p38 MAP kinase phosphorylation might be dependent on the concentration of C 2 -ceramide used. Hsu et al. 11 used 50 mM C 2 -ceramide for the treatment of RAW 264.7 cells. In our case, RAW 264.7 cells were treated with O 15 mM C 2 -ceramide since 50 mM C 2 -ceramide exhibited a strong cytotoxicity on RAW 264.7 cells and shut off most of signal pathways.
Medvedev et al. 13 reported that C 2 -ceramide activates MAP kinases including p38, ERK1/2 and SAPK/JNK, but not NF-kB. C 2 -ceramide-mediated activation of p38 MAP kinase was reproduced in the present study. However, we could not find C 2 -ceramide-mediated activation of ERK1/2 and SAPK/JNK. C 2 -ceramide did not affect LPS-induced activation of p38 MAP kinase in the present study. Therefore, it is unlikely that C 2 -ceramide inhibits LPS-induced NO production through the impairment of a series of MAP kinases. Further, Knapp and English 9 reported that cell-permeable analogs of ceramide up-regulate iNOS expression in RAW 264.7 cells via tyrosine kinases. Their finding could not be reproduced in our study.
CONCLUSIONS
In the present study, we demonstrated that C 2 -ceramide might modulate LPS-induced NO production through the inhibition of Akt activation. C 2 -ceramide could be used to characterize the detailed mechanism of LPS signaling and further to regulate LPS-induced macrophage activation.
